Fujian Wanchen Biotechnology Co. Ltd (300972) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Fujian Wanchen Biotechnology Co. Ltd stock ¥88.62, price ¥130, that is 31.6% below the price, quality 60 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range ¥10.22 – ¥232.67 · fair‑value band ¥45.77 – ¥141.09 · the ¥129.60 price screens above the ¥88.62 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow Fujian Wanchen Biotechnology Co. in your weekly email
Every Wednesday you see whether Fujian Wanchen Biotechnology Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Fujian Wanchen Food Group Co., Ltd., together with its subsidiaries, engages in the research, development, cultivation, production, and sale of edible fungi in China and internationally.
Show moreShow less
The company provides white and golden enoki, crab, white jade, deer antler, seafood, oyster, and other mushrooms products. It is also involved in breeding and fruit testing to produce new variants of edible fungi.
The company sells its products through supermarket chains, restaurants, and online food platforms. It exports its products. The company was formerly known as Fujian Wanchen Biotechnology Group Co.,Ltd. and changed its name to Fujian Wanchen Food Group Co., Ltd. in January 2026.
Fujian Wanchen Food Group Co., Ltd. was founded in 2011 and is headquartered in Zhangpu, China.
Stock analysis
Fujian Wanchen Biotechnology Co. Ltd (300972) currently trades at ¥129.60, while our model-based Fair Value estimate is ¥88.62, 32% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥310.08 per share, and 16 of the 26 models we run sit above the ¥129.60 price.
Bear case: the Economic Profit group reads lowest at ¥64.02, and 10 of the 26 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ¥45.77 (bear) to ¥141.09 (bull), the price of ¥129.60 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Consumer Defensive sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Fujian Wanchen Biotechnology Co. Ltd reported revenue of 51.5B CNY in FY2025 versus 435M CNY in FY2021, a compound +229.9%/yr. Reported net income was 1.3B CNY in FY2025, compounding +175.2%/yr from FY2021.
Key figures
Market cap 26.7B CNY (≈ $4.0B) Mid · P/E ratio 11.2 · P/S ratio 0.35 · EPS (TTM) ¥11.60 · Dividend yield 0.7% · Net margin 3.3% · Return on equity 88.3% · Return on assets (EBIT) 11.0% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 44% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at 6% fair-value upside, at −32%, 300972 screens richer than that median.
Fair Value models
Bear¥45.77Fair Value ¥88.62Bull¥141.09
Price ¥129.60 · Downside -31.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥9.19 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF¥155.64¥226.45¥440.9873
Growth DCF¥146.55¥253.69¥423.1373
5Y EBITDA Exit¥124.08¥202.28¥355.2670
All 26 models by family
DCF Models
FCF DCF¥155.64¥226.45¥440.9873
Owner Earnings¥137.19¥279.54¥551.7268
5Y Revenue Exit¥119.02¥192.06¥344.4067
5Y EBITDA Exit¥124.08¥202.28¥355.2670
5Y P/E Exit¥130.76¥265.49¥446.7365
10Y Revenue Exit¥128.46¥253.20¥327.8363
10Y EBITDA Exit¥135.29¥263.40¥479.1062
10Y P/E Exit¥139.87¥276.87¥496.5258
Earnings-Based
Graham-Dodd¥46.06¥321.20¥450.7561
Lynch FV¥165.94¥237.06¥308.1859
PEG = 1.0¥165.94¥237.06¥308.1855
EPV¥71.84¥80.67¥88.1370
Dividend Discount
Gordon GGM¥4.00¥7.46¥10.6065
DDM Multi-Stage¥4.00¥6.69¥7.9465
Multiples
P/E Multiple¥106.68¥142.24¥177.8063
P/S Multiple¥86.36¥115.14¥143.9357
P/B Multiple¥29.14¥38.85¥48.5655
EV/EBIT¥117.45¥156.73¥196.0265
EV/EBITDA¥96.86¥129.28¥161.7067
EV/Revenue¥83.71¥119.76¥155.8153
Asset-Based
NCAV (Graham)¥2.80¥4.24¥5.3054
Growth DCF
Growth DCF¥146.55¥253.69¥423.1373
Rev-Margin DCF¥129.93¥218.22¥403.3366
Economic Profit
Residual Income¥25.97¥47.36¥135.5262
ROIC Compounder¥71.84¥80.67¥88.1369
Growth Earnings
Growth-Adj P/E¥217.05¥310.08¥403.1065
The fair value above starts from this blend and is adjusted for a cyclical peak year.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+59.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+354.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+158.0%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+120.2%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
≈ +55.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+54.8%
Dividend (yield on the price)0.7%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.23% → 6%
⚠ Approximate: the rate leans on 2025, which sits 633% above its own trend.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−10.9%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+22.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −12.4% a year for the price and +20.6% for the forecasts.
Compare Fujian Wanchen Biotechnology Co. Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Farm Products · 291 stocks
Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score60 · Above median
Fair Value upside−31.6% · Below median
Profitability
Return on equity (12 months)88.3% · Top 25%
Return on assets24.1% · Top 25%
Net margin (12 months)6.0% · Above median
Operating margin (12 months)6.9% · Above median
Growth and dividend
Revenue growth (quarter YoY)48.7% · Top 25%
Dividend yield (12 months)0.7% · Bottom 25%
Balance sheet
Debt / equity0.66× · Highest 25%
Valuation Multiplesvs Farm Products median · lower = cheaper
P/E (12 months)11.2× · Cheaper than median
P/B17.97× · Priciest 25%
P/S (12 months)0.68× · Cheaper than median
Price / free cash flow (fiscal year)13.5× · Pricier than median
EV/EBITDA8.4× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 27
FUTURE (revenue growth)100· sector 15
PAST (return on equity)100· sector 17
HEALTH (low debt)67· sector 94
DIVIDEND (yield)13· sector 41
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Fujian Wanchen Biotechnology Co. Ltd (300972) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of ¥88.62 versus a price of ¥129.60, about 32% lower (overvalued).
What is the fair value of 300972?
Our model-based fair value for Fujian Wanchen Biotechnology Co. Ltd is ¥88.62 (as of Nov 4, 2026), built from audited fundamentals. The current price: ¥129.60.
What is the quality score of 300972?
Fujian Wanchen Biotechnology Co. Ltd has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Fujian Wanchen Biotechnology Co. Ltd (300972)?
Our model-based price target is the fair value of ¥88.62 (as of Nov 4, 2026) from 26 valuation models. Cautious scenario ¥45.77, optimistic scenario ¥141.09. It is a calculation from audited fundamentals, not an analyst target.
What is the Fujian Wanchen Biotechnology Co. Ltd stock forecast for 2026?
Our models put fair value at ¥88.62, about 32% lower versus a price of ¥129.60 (overvalued). Cautious scenario ¥45.77, optimistic scenario ¥141.09. The calculation is refreshed regularly with new filings.
What is the revenue of Fujian Wanchen Biotechnology Co. Ltd (300972)?
Fujian Wanchen Biotechnology Co. Ltd reported trailing-twelve-month revenue of about 70.5B CNY (latest available figure, as of Nov 4, 2026).
Does Fujian Wanchen Biotechnology Co. Ltd pay a dividend?
Fujian Wanchen Biotechnology Co. Ltd currently shows a dividend yield of 0.66% relative to its recent price (as of Nov 4, 2026).
How much is the dividend of Fujian Wanchen Biotechnology Co. Ltd (300972) and when is the ex-dividend date?
Fujian Wanchen Biotechnology Co. Ltd pays a dividend of ¥0.85 per share a year, a dividend yield of 0.7%. The last ex-dividend date was Sep 24, 2026. The payout ratio is 7.3% of earnings. Free cash flow covers the dividend 21.06 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Fujian Wanchen Biotechnology Co. Ltd (300972)?
For today's price to be fair in a discounted-cash-flow model, Fujian Wanchen Biotechnology Co. Ltd would have to grow free cash flow by -10.9 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +158.0 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of 300972 use?
Our models discount Fujian Wanchen Biotechnology Co. Ltd at 10.4 %: a base by market capitalisation (mid), country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Fujian Wanchen Biotechnology Co. Ltd that is -10.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Fujian Wanchen Biotechnology Co. Ltd (300972) delivered so far?
Over the past 5 years revenue at Fujian Wanchen Biotechnology Co. Ltd grew +158.0 % a year. The price currently implies free-cash-flow growth of -10.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Fujian Wanchen Biotechnology Co. Ltd (300972) growing?
The median revenue growth in the sector is +3.6 % a year. That is the yardstick for the growth priced into Fujian Wanchen Biotechnology Co. Ltd (-10.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Fujian Wanchen Biotechnology Co. Ltd (300972)?
The free-cash-flow yield on the price is 14.52 %: that much free cash flow Fujian Wanchen Biotechnology Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Fujian Wanchen Biotechnology Co. Ltd (300972)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Fujian Wanchen Biotechnology Co. Ltd it is ¥88.62 per share (as of Nov 4, 2026), against a price of ¥129.60. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Fujian Wanchen Biotechnology Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 4, 2026, 300972 trades above its calculated fair value: price ¥129.60, fair value ¥88.62, a gap of about −32% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300972?
No. The price is what the market pays today (¥129.60); the fair value is what the company's own numbers justify (¥88.62). For Fujian Wanchen Biotechnology Co. Ltd the two are ¥40.98 per share apart. That gap is exactly why we show both numbers side by side.
How much is Fujian Wanchen Biotechnology Co. Ltd worth?
The market values Fujian Wanchen Biotechnology Co. Ltd at about 26.7B CNY (market capitalisation, as of Nov 4, 2026). Per share that is ¥129.60; our models calculate a fair value of ¥88.62 per share.
What do the bullish and bearish scenarios say about 300972?
Our models span a range for Fujian Wanchen Biotechnology Co. Ltd: cautious scenario ¥45.77, base ¥88.62, optimistic ¥141.09 per share (as of Nov 4, 2026, price ¥129.60). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 300972?
Fujian Wanchen Biotechnology Co. Ltd trades at a price-to-earnings ratio of 11.2 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥88.62 is built from several models across several years. Other multiples: P/B 18.0, P/S 0.7, EV/EBITDA 8.4.
How solid is the balance sheet of Fujian Wanchen Biotechnology Co. Ltd (300972)?
Balance-sheet figures for Fujian Wanchen Biotechnology Co. Ltd (as of Nov 4, 2026): return on equity 88.3%, debt of 0.66 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is 300972 from its 52-week high?
Fujian Wanchen Biotechnology Co. Ltd trades at ¥129.60, about 44% below its 52-week high of ¥232.67 and at the low of ¥129.60 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥88.62 is for.
Which stocks are comparable to Fujian Wanchen Biotechnology Co. Ltd?
From the same area (Consumer Defensive) we also value Muyuan Foods Group, Archer-Daniels-Midland Company, Tyson Foods, Inc, Bunge Global SA, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Fujian Wanchen Biotechnology Co. Ltd stock attractive at the current price?
The data as of Nov 4, 2026: price ¥129.60, calculated fair value ¥88.62 (−32%), Quality Score 60/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300972 calculated?
We run Fujian Wanchen Biotechnology Co. Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥88.62 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Fujian Wanchen Biotechnology Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Fujian Wanchen Biotechnology Co. Ltd (300972)?
The closing price on Nov 6, 2026 was ¥129.60. Our model-based fair value is ¥88.62, about 32% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Fujian Wanchen Biotechnology Co. Ltd right now?
The model range is unusually wide (¥45.77 to ¥141.09). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Fujian Wanchen Biotechnology Co. Ltd
How large is the market capitalisation of Fujian Wanchen Biotechnology Co. Ltd (300972)?
The market capitalisation of Fujian Wanchen Biotechnology Co. Ltd is 26.7B CNY (≈ $4.0B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Fujian Wanchen Biotechnology Co. Ltd (300972)?
The price-to-sales ratio of Fujian Wanchen Biotechnology Co. Ltd is 0.35 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Fujian Wanchen Biotechnology Co. Ltd (300972)?
Earnings per share at Fujian Wanchen Biotechnology Co. Ltd are ¥11.60 (price ÷ EPS = P/E 11.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Fujian Wanchen Biotechnology Co. Ltd (300972)?
The dividend yield of Fujian Wanchen Biotechnology Co. Ltd is 0.7% (payout 7.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Fujian Wanchen Biotechnology Co. Ltd (300972)?
The net margin of Fujian Wanchen Biotechnology Co. Ltd is 3.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Fujian Wanchen Biotechnology Co. Ltd (300972)?
The return on equity (ROE) of Fujian Wanchen Biotechnology Co. Ltd is 88.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Fujian Wanchen Biotechnology Co. Ltd (300972)?
On an EBIT basis the return on assets of Fujian Wanchen Biotechnology Co. Ltd is 11.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Fujian Wanchen Biotechnology Co. Ltd (300972)?
The operating margin of Fujian Wanchen Biotechnology Co. Ltd is 6.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Fujian Wanchen Biotechnology Co. Ltd (300972)?
Revenue at Fujian Wanchen Biotechnology Co. Ltd is growing +48.7% versus a year earlier (3y avg +354%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Fujian Wanchen Biotechnology Co. Ltd (300972)?
Earnings per share at Fujian Wanchen Biotechnology Co. Ltd are growing +61.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Fujian Wanchen Biotechnology Co. Ltd (300972) carry?
The net debt of Fujian Wanchen Biotechnology Co. Ltd is 144M CNY (fiscal year 2022, ≈ 0.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Fujian Wanchen Biotechnology Co. Ltd in the live analysis
One click puts Fujian Wanchen Biotechnology Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 4, 2026